Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia. by McKemey, Emily et al.
LETTER TO EDITOR
Resolution of Persistent COVID-19 After Convalescent Plasma
in a Patient with B Cell Aplasia
Emily McKemey1 & Adrian M. Shields1,2 & Sian E. Faustini2 & Harriet J. Hill3 & Aliaksandra Barnskaya1 &
Zania Stamataki3 & Simon Gompertz1 & Alex G. Richter1,2 & Davinder Dosanjh1 & Shyam Madathil1
Received: 23 December 2020 /Accepted: 11 February 2021
# The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021
To the Editor,
We read with interest the report from London et al. regarding
the efficacy of convalescent plasma in the treatment of severe
COVID-19 in two patients with primary immunodeficiencies
[1]. Herein, we highlight our experience of using remdesivir
and convalescent plasma to treat persistent symptomatic
COVID-19 in a patient with secondary immunodeficiency
following long-term rituximab treatment.
Case Report
A 57-year-old lady presented to the emergency department on
16/4/2020 with shortness of breath, a 2-week history of dry
cough, pyrexia (38.4 °C), and raised inflammatory markers.
Chest radiography demonstrated bilateral and lower-zone pe-
ripheral air space opacities; however, she was not hypoxic.
She had a 13-year history of anti-CCP seropositive rheuma-
toid arthritis, previously treated with glucocorticoids, disease-
modifying anti-rheumatic drugs, etanercept, and, most recent-
ly, 6-monthly rituximab infusions commenced in 2014. Her
last dose of rituximab was on 13/3/2020, approximately 3
weeks prior to the onset of symptoms. Serial immunoglobulin
measurements are shown in Fig. 1a. The patient had
previously suffered from intermittent lower respiratory tract
infections with fully sensitive Streptococcus pneumoniae and
non-typable Haemophilus influenzae previously grown in the
sputum, despite protective IgG antibody concentrations in 8
out of 12 measured pneumococcal serotypes (Supplementary
Table 1).
A diagnosis of likely COVID-19 was made, but not proven
by polymerase chain reaction (PCR) studies; the patient was
discharged with broad-spectrum, oral antibiotics but re-
represented 8 days later with persistent pyrexia (39.2 °C),
cough, dyspnoea, and new diarrhea and vomiting.
Inflammatory markers remained elevated and she was admit-
ted for treatment with intravenous antibiotics and fluids. Three
nasopharyngeal swabs taken within the first 3 days of admis-
sion returned negative results; however, radiological progres-
sion suggested ongoing viral pneumonia; SARS-CoV-2 RNA
was first detected in a sputum sample on day 25 and subse-
quently found on multiple nasopharyngeal swabs between
May and July 2020.
Between May and July 2020, she was re-admitted to the
hospital on four occasions with similar symptoms, increasing
oxygen requirements (peak oxygen requirements 4 L via nasal
cannula to achieve peripheral oxygen saturation of 96%;
desaturation to 82% on room air on exertion) and progressive
radiological changes (Supplementary Figure 1). Blood cul-
tures, urine cultures, sputum cultures, sputum mycobacterial
PCR, and virology for cytomegalovirus and Epstein-Barr vi-
rus undertaken during these admissions did not identify an-
other concurrent infection. During these admissions, she re-
ceived three separate courses dexamethasone (6 mg once dai-
ly, orally; one 7-day course; two 10-day courses) and one
course of remdesivir (200-mg loading dose followed by
100 mg once daily, 10 days, intravenously). Monotherapy
with dexamethasone achieved little objective change in phys-
iological and biochemical parameters of infection but treat-
ment with intravenous remdesivir was associated with a dra-
matic reduction in C-reactive protein (Fig. 1b). Twenty-four
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hours after the cessation of remdesivir, a rebound increase in
CRP and temperature was observed suggestive of a release of
suppression of viral replication; SARS-CoV-2 RNA remained
detectable following nasopharyngeal swabbing. Despite
prolonged PCR positivity, anti-spike and anti-nucleocapsid
SARS-CoV-2 antibodies were not detectable in the patient’s
serum by mid-July 2020 secondary to ongoing, complete,
peripheral B cell aplasia. On day 99, the patient received
two units of convalescent plasma (275 mL/unit, units were
centrally pre-screened by the NHS Blood Transfusion
Service for a SARS-CoV-2 neutralizing antibody titer greater
than 1:100). Convalescent plasma was well tolerated with
rapid symptomatic improvement, reduction in inflammatory
markers, and defervescence.
Following the administration of convalescent plasma,
SARS-CoV-2 PCR was not detected on seven consecutive
swabs taken between day 101 and day 119. IgG but not IgA
or IgM antibodies directed against the spike protein remained
detectable in the patients’ serum 3 weeks following adminis-
tration of the plasma product (Fig. 1c). A serum sample taken
7 days after the administration of convalescent plasma showed
> 95% neutralization of SARS-CoV-2 infectivity at a 1/200
dilution compared to pre-convalescent plasma serum (Fig.
1d). Neutralizing activity had been lost by day 119. A full
description of the neutralizing assay is available in the supple-
mentary methods. Resolution of plain-film radiological
changes was observed by day 154 (Supplementary Figure 1).
Discussion
Adults with primary and secondary immunodeficiencies are at
increased risk of morbidity and mortality from COVID-19
compared to the general population [2]. There are limited
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Fig. 1 a Serial serum IgG (gray), IgA (blue), and IgM (red) measure-
ments over time. Normal ranges are shown by dotted lines. Asterisk “*”
represents date rituximab was initiated. b Changes in peripheral blood
neutrophil count, lymphocyte count, C-reactive protein, and temperature
over the time course of disease relative to pharmacological treatments
received. Time course is relative to the first presentation on 16/4/2020.
c Level of serum IgG, IgA, and IgM anti-SARS-CoV-2 trimeric spike
glycoprotein antibodies were measured before and after treatment with
convalescent plasma. Results are expressed as a signal to the cutoff cal-
ibrator ratio with the dotted line representing the cutoff for positivity. d
In vitro SARS-CoV-2 neutralizing activity of serum from the patient
before (day 91) and after (day 106 and day 119) the administration of
convalescent plasma. Dex, dexamethasone; PCR, polymerase chain reac-
tion; CT, cycle threshold; TMA, transcription-mediated amplification
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treatments for severe COVID-19; of the empirical treatments
used in this study (dexamethasone, remdesivir, convalescent
plasma), the only dexamethasone is associated with reduced
28-day mortality in the general population [3–5]. Whether the
results from these large trials can be rationally generalized to
patients with immune deficiencies is unknown.
Remdesivir is a ribonucleotide analog that inhibits the
SARS-CoV-2 RNA-dependent RNA polymerase and arrests
viral RNA synthesis by acting as a delayed chain terminator
[6]. Concordant with previous case reports (Supplementary
Table 2), we found the administration of remdesivir was as-
sociated with significant improvements in immunological and
physiological biomarkers of SARS-CoV-2 infection.
However, the rapid recrudescence of symptomatic COVID-
19 following the cessation of remdesivir supports the hypoth-
esis that remdesivir monotherapy is insufficient to support
virological clearance and resolution of COVID-19 in patients
with humoral immunodeficiency.
In our patient, and others treated with both remdesivir
and convalescent plasma (summarized in Supplementary
Table 2), complete virological clearance and prolonged
symptomatic resolution were only achieved following the
administration of convalescent plasma. The efficacy of
convalescent plasma in the treatment of COVID-19 in
patients has been reported in small case series of individ-
uals with both congenital and acquired B cell aplasia
[7–9]. Of note, two reports demonstrate that viral persis-
tence can occur despite the generation of CD4 and CD8 T
cell responses to viral antigens and that magnitude of
ex vivo antiviral T cell responses is augmented following
the administration of convalescent plasma [10, 11]. These
data point to a non-redundant role for humoral immunity
in immunological control of SARS-CoV-2, potentially via
mechanisms such as antibody-dependent cellular cytotoxic-
ity or opsonization, and suggest convalescent plasma is a
rational therapeutic choice for individuals with humoral
immune deficiencies, particularly when current immuno-
globulin replacement products lack SARS-CoV-2-specific
antibodies [12].
However, the administration of convalescent plasma to im-
munodeficient patients has been associated with the emer-
gence of novel genomic variants within SARS-CoV-2
encoding spike proteins that demonstrate reduced susceptibil-
ity to neutralization in vitro [13]. Thus, combination treat-
ments that simultaneously suppress viral RNA synthesis and
facilitate viral clearance may be appropriate in immunocom-
promised individuals, to prevent the emergence of novel viral
variants. A more comprehensive understanding of mecha-
nisms through which convalescent plasma mediates its thera-
peutic effect and how these mechanisms are defective in pri-
mary and secondary immune deficiency may allow the selec-
tion of individuals who would benefit from such
interventions.
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